JP2023511780A - コロナウイルスに対するワクチンおよび使用方法 - Google Patents

コロナウイルスに対するワクチンおよび使用方法 Download PDF

Info

Publication number
JP2023511780A
JP2023511780A JP2022551031A JP2022551031A JP2023511780A JP 2023511780 A JP2023511780 A JP 2023511780A JP 2022551031 A JP2022551031 A JP 2022551031A JP 2022551031 A JP2022551031 A JP 2022551031A JP 2023511780 A JP2023511780 A JP 2023511780A
Authority
JP
Japan
Prior art keywords
cov
sars
nucleic acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022551031A
Other languages
English (en)
Japanese (ja)
Inventor
イェン チエン
ブロデリック ケイト
ウェイナー デイビッド
ムツマニ カー
パテル アミ
Original Assignee
イノビオ ファーマシューティカルズ，インコーポレイティド
ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イノビオ ファーマシューティカルズ，インコーポレイティド, ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー filed Critical イノビオ ファーマシューティカルズ，インコーポレイティド
Publication of JP2023511780A publication Critical patent/JP2023511780A/ja
Priority to JP2024184185A priority Critical patent/JP2025010171A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/20044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022551031A 2020-02-25 2021-02-25 コロナウイルスに対するワクチンおよび使用方法 Withdrawn JP2023511780A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024184185A JP2025010171A (ja) 2020-02-25 2024-10-18 コロナウイルスに対するワクチンおよび使用方法

Applications Claiming Priority (29)

Application Number Priority Date Filing Date Title
US202062981451P 2020-02-25 2020-02-25
US202062981168P 2020-02-25 2020-02-25
US62/981,168 2020-02-25
US62/981,451 2020-02-25
US202063004380P 2020-04-02 2020-04-02
US63/004,380 2020-04-02
US202063022032P 2020-05-08 2020-05-08
US63/022,032 2020-05-08
US202063028404P 2020-05-21 2020-05-21
US63/028,404 2020-05-21
US202063033349P 2020-06-02 2020-06-02
US63/033,349 2020-06-02
US202063040865P 2020-06-18 2020-06-18
US63/040,865 2020-06-18
US202063046415P 2020-06-30 2020-06-30
US63/046,415 2020-06-30
US202063056996P 2020-07-27 2020-07-27
US63/056,996 2020-07-27
US202063063157P 2020-08-07 2020-08-07
US202063062762P 2020-08-07 2020-08-07
US63/062,762 2020-08-07
US63/063,157 2020-08-07
US202063114858P 2020-11-17 2020-11-17
US63/114,858 2020-11-17
US202063130593P 2020-12-24 2020-12-24
US63/130,593 2020-12-24
US202163136973P 2021-01-13 2021-01-13
US63/136,973 2021-01-13
PCT/US2021/019662 WO2021173829A1 (en) 2020-02-25 2021-02-25 Vaccines against coronavirus and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024184185A Division JP2025010171A (ja) 2020-02-25 2024-10-18 コロナウイルスに対するワクチンおよび使用方法

Publications (1)

Publication Number Publication Date
JP2023511780A true JP2023511780A (ja) 2023-03-22

Family

ID=75108858

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022551031A Withdrawn JP2023511780A (ja) 2020-02-25 2021-02-25 コロナウイルスに対するワクチンおよび使用方法
JP2024184185A Pending JP2025010171A (ja) 2020-02-25 2024-10-18 コロナウイルスに対するワクチンおよび使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024184185A Pending JP2025010171A (ja) 2020-02-25 2024-10-18 コロナウイルスに対するワクチンおよび使用方法

Country Status (15)

Country Link
US (3) US11660335B2 (enExample)
EP (1) EP4110468A1 (enExample)
JP (2) JP2023511780A (enExample)
KR (1) KR20220157969A (enExample)
CN (1) CN115867349A (enExample)
AU (2) AU2021226567B2 (enExample)
BR (1) BR112022016507A2 (enExample)
CA (1) CA3168353A1 (enExample)
CO (1) CO2022012272A2 (enExample)
CU (1) CU24743B1 (enExample)
IL (1) IL295697A (enExample)
MX (1) MX2022010460A (enExample)
PE (1) PE20230171A1 (enExample)
PH (1) PH12022552249A1 (enExample)
WO (1) WO2021173829A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252604A1 (en) * 2020-06-09 2021-12-16 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
EP4333887A4 (en) * 2021-05-05 2025-05-21 Inovio Pharmaceuticals, Inc. Vaccines against coronavirus and methods of use
WO2023035016A1 (en) * 2021-09-03 2023-03-09 The Uab Research Foundation Human neutralizing antibodies against sars-cov-2 spike s2 domain and uses thereof
WO2023073672A1 (en) * 2021-10-29 2023-05-04 Geneone Life Science, Inc. Therapeutic and vaccine candidates against sars-cov-2
WO2024231886A1 (en) * 2023-05-10 2024-11-14 Seqirus Inc. Combination vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025788A1 (en) * 2003-06-06 2005-02-03 Chou George Chin-Sheng Systemic delivery of non-viral vector expressing SARS viral genomic vaccine
JP2016539946A (ja) * 2013-11-29 2016-12-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＥＲＳ‐ＣｏＶワクチン

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
CA2337129A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
CA2369329A1 (en) 1999-05-10 2000-11-16 Gunter A. Hofmann Method of electroporation-enhanced delivery of active agents
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230075527A1 (en) 2020-01-31 2023-03-09 Janssen Pharmaceuticals, Inc Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025788A1 (en) * 2003-06-06 2005-02-03 Chou George Chin-Sheng Systemic delivery of non-viral vector expressing SARS viral genomic vaccine
JP2016539946A (ja) * 2013-11-29 2016-12-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＭＥＲＳ‐ＣｏＶワクチン

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CELL HOST & MICROBE, vol. 27, JPN6023041587, 7 February 2020 (2020-02-07), pages 325 - 328, ISSN: 0005466899 *

Also Published As

Publication number Publication date
US20210268102A1 (en) 2021-09-02
PH12022552249A1 (en) 2023-11-13
US20230338515A1 (en) 2023-10-26
US11660335B2 (en) 2023-05-30
KR20220157969A (ko) 2022-11-29
AU2025205555A1 (en) 2025-08-07
EP4110468A1 (en) 2023-01-04
CO2022012272A2 (es) 2022-11-29
AU2021226567A1 (en) 2022-10-13
WO2021173829A1 (en) 2021-09-02
CU20220050A7 (es) 2023-04-10
JP2025010171A (ja) 2025-01-20
PE20230171A1 (es) 2023-02-01
CU24743B1 (es) 2025-03-10
AU2021226567B2 (en) 2025-04-17
MX2022010460A (es) 2022-09-19
BR112022016507A2 (pt) 2022-11-22
CA3168353A1 (en) 2021-09-02
IL295697A (en) 2022-10-01
CN115867349A (zh) 2023-03-28
US20250121054A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
US20250121054A1 (en) Vaccines against coronavirus and methods of use
US11382968B2 (en) Coronavirus immunogenic compositions and uses thereof
CN109152826B (zh) 新抗寨卡病毒疫苗
US20190091322A1 (en) Dna antibody constructs and method of using same
CN105939730A (zh) MERS-CoV疫苗
US20210260181A1 (en) Coronavirus immunogenic compositions and uses thereof
AU2021236141B2 (en) Treatment of covid-19 and methods therefor
US11925685B2 (en) DNA antibody constructs encoding anti-ZIKV envelope antibodies
Collett et al. Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates
EP4333887A1 (en) Vaccines against coronavirus and methods of use
CN117479953A (zh) 针对冠状病毒的疫苗及其使用方法
HK40091328A (zh) 针对冠状病毒的疫苗和使用方法
EA046179B1 (ru) Вакцины против коронавируса и способы их применения
US20230210981A1 (en) Coronavirus disease 2019 (covid-19) combination vaccine
US11857620B2 (en) Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241023

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241112

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241202

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241129